JP2015513521A5 - - Google Patents

Download PDF

Info

Publication number
JP2015513521A5
JP2015513521A5 JP2014543711A JP2014543711A JP2015513521A5 JP 2015513521 A5 JP2015513521 A5 JP 2015513521A5 JP 2014543711 A JP2014543711 A JP 2014543711A JP 2014543711 A JP2014543711 A JP 2014543711A JP 2015513521 A5 JP2015513521 A5 JP 2015513521A5
Authority
JP
Japan
Prior art keywords
group
carbon atoms
alkyl
disorder
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543711A
Other languages
English (en)
Japanese (ja)
Other versions
JP6415982B2 (ja
JP2015513521A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014543711A priority Critical patent/JP6415982B2/ja
Priority claimed from JP2014543711A external-priority patent/JP6415982B2/ja
Publication of JP2015513521A publication Critical patent/JP2015513521A/ja
Publication of JP2015513521A5 publication Critical patent/JP2015513521A5/ja
Application granted granted Critical
Publication of JP6415982B2 publication Critical patent/JP6415982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543711A 2012-03-12 2013-03-11 複素環化合物 Active JP6415982B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014543711A JP6415982B2 (ja) 2012-03-12 2013-03-11 複素環化合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012054467 2012-03-12
JP2012054467 2012-03-12
JP2014543711A JP6415982B2 (ja) 2012-03-12 2013-03-11 複素環化合物
PCT/JP2013/057923 WO2013137479A1 (en) 2012-03-12 2013-03-11 Decahydroquinoxaline derivatives and analogs thereof

Publications (3)

Publication Number Publication Date
JP2015513521A JP2015513521A (ja) 2015-05-14
JP2015513521A5 true JP2015513521A5 (enExample) 2016-04-21
JP6415982B2 JP6415982B2 (ja) 2018-10-31

Family

ID=48048149

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014543711A Active JP6415982B2 (ja) 2012-03-12 2013-03-11 複素環化合物

Country Status (4)

Country Link
JP (1) JP6415982B2 (enExample)
AR (1) AR090312A1 (enExample)
TW (1) TW201348215A (enExample)
WO (1) WO2013137479A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015196086A1 (en) * 2014-06-20 2015-12-23 The University of Montana, Missoula, MT NOVEL INHIBITORS OF SYSTEM Xc(-)
AU2022312844A1 (en) * 2021-07-13 2024-01-04 Otsuka Pharmaceutical Co., Ltd. Hydrogenated quinoxalines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4210941A1 (de) * 1992-04-02 1993-10-07 Bayer Ag Neue 9-Fluor-7.oxo-7H-pyrido[1,2,3-d,e][1,4]benzoxacin-6-carbonsäuren und -ester
DE69919436T2 (de) * 1998-04-16 2005-09-15 Pfizer Products Inc., Groton N-Acyl und N-Aroyl Aralkylamide
IT1312310B1 (it) * 1999-05-07 2002-04-15 Recordati Ind Chimica E Farma Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
CA2553291A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. Combination of .gamma.-aminobutyric acid modulators and 5-ht1b receptor antagonists
WO2008019372A2 (en) * 2006-08-07 2008-02-14 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5ht3 modulators
US20120077795A1 (en) * 2009-06-03 2012-03-29 Glaxsmithkline Llc Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
WO2011068171A1 (ja) * 2009-12-03 2011-06-09 第一三共株式会社 二環性含窒素飽和へテロ環誘導体
ES2553387T3 (es) * 2010-09-13 2015-12-09 Otsuka Pharmaceutical Co., Ltd. Compuestos heterocíclicos para el tratamiento o la prevención de trastornos causados por neurotransmisión reducida de serotonina, norepinefrina o dopamina

Similar Documents

Publication Publication Date Title
AU2010339423B9 (en) Therapeutic compounds and related methods of use
JP2022153616A (ja) Ｓｈｐ２阻害剤として有用な新規複素環式誘導体
TW200526604A (en) Methods for synthesizing quinolinone compounds
EP3536324B1 (en) 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139
WO2013003586A1 (en) Quinazolines as therapeutic compounds and related methods of use
AU2015335783B2 (en) Tricyclic atropisomer compounds
CA2651363A1 (en) Triazolopyrazine derivatives useful as anti-cancer agents
US20170342054A1 (en) Compounds and methods of use thereof
CA2564994A1 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
HUP0301932A2 (hu) IL-1béta és TNF-a inhibitor benzofenon származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása gyógyszerkészítmények elżállítására
JPWO2020017587A5 (enExample)
CN105722840B (zh) 作为PI3K、mTOR抑制剂的稠合喹啉化合物
JP2020511515A5 (enExample)
JP2017517538A (ja) Ｇａｂａａ受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
TW201536774A (zh) 經取代之四氫咔唑及咔唑甲醯胺化合物
JP2019535825A5 (enExample)
JP2007500168A5 (enExample)
HRP20151282T1 (hr) Heterocikliäśki spojevi za lijeäśenje ili prevenciju bolesti izazvanih smanjenom neurotransmisijom serotonina, norepinefrina ili dopamina
WO2007093829A1 (en) 3-aminopyrazolines for treatment of neurodegenerative and psychiatric diseases
CZ295747B6 (cs) Substituované benzylaminy a farmaceutický prostředek
JP2005538974A5 (enExample)
MX2007015678A (es) Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a.
JP2006511498A5 (enExample)
JP2015513521A5 (enExample)
CN104364253A (zh) 作为kat ii抑制剂的三环化合物